Founder of NovImmune, and former professor and director of the Department of Genetics and Microbiology, Faculty of Medicine, University of Geneva, Bernard Mach is the inventor of cDNA cloning and is specialized in the molecular biology of immune response genes. Bernard was co-founder and member of the SAB of Biogen (1978-1992). He was Chairman of the Lombard Odier Immunology Fund Scientific Advisory Board from 1994 to 2002. Former member of the Board of Directors of Serono and former board member of Lonza as well as Scientific Advisor to various institutes and companies. He was a Member of the Swiss Science Council (1974-1984), is a special member of the Swiss Academy of Medical Sciences and is a Member of the French Academy of Sciences. He is now Chairman of the SAB of Aravis Venture Associates.

Bart N. Lambrecht obtained the MD/PhD degree at the University of Ghent, Belgium; thereafter he moved to The Netherlands where he trained in Pulmonary Medicine. He became Professor of Pulmonary Medicine in 2005, holding a special chair in Immunopathology of the Lung at the pulmonary research program of Erasmus University, Rotterdam, The Netherlands. After ten years in The Netherlands, he moved back to Belgium and was appointed Professor of Pulmonary Medicine at Ghent University, and is currently heading a group dealing with the immunopathology of asthma and immunotherapy of cancer. He is the author of over 100 papers dealing with the use of mouse models to study the pathogenesis of asthma and cancer related immunosuppression. He has received several awards, among which the Odysseus Grant of the Flemish government, The Inbev-Baillet Latour Prize for Clinical Research, The Pharmacia Allergy Research Foundation Award 2004, The NWO Vidi scholarship, The Schering Plough Respiratory 2000 Award, and the 1998 European Respiratory Society Annual Allergy and Immunology award. He is a Young Academy member of the Royal Dutch Academy of Arts and Sciences (KNAW), advisory editor of The Journal of Experimental Medicine and associate editor of Mucosal Immunology.

Professor Paul-Peter Tak is Director of the Division of Clinical Immunology and Rheumatology at the Academic Medical Center (AMC)/University of Amsterdam in Amsterdam, the Netherlands. Following his undergraduate medical studies, Professor Tak received his medical degree at the Free University (VU) Amsterdam, and was trained at Leiden University Medical Centre, where he also received his PhD degree. He has worked as a visiting scientist at UCSD (La Jolla, CA) for 2 years and was affiliated with this university as Clinical Associate Professor for a further 5 years. From 2004 to 2008 he also served as Medical Director of the Dubai Bone and Joint Centre (Dubai, UAE). He founded in 2005 Arthrogen B.V., a company developing gene therapy, and has served as Chief Scientific Officer since then. Professor Tak has been principal investigator for more than 25 clinical trials and received numerous grantsm honours and fellowships. His major research interests include signal transduction pathways, the pathogenesis of synovial inflammation in rheumatoid and psoriatic arthritis and the development and evaluation of immunotherapies and gene therapy for these conditions.Professor Tak is a member of the EULAR (European League against Rheumatism) Scientific Committee, member of ACR (American College of Rheumatology) Scientific Committee, and Chairman of the Grant Advisory Council for EULAR's Orphan Disease Programme (ODP) on systemic sclerosis. His extensive bibliography includes a list of more than 250 peer-reviewed clinical and basic research papers, as well as books on various aspects of immunology and rheumatology.

Sander van Deventer is currently a General Partner at Forbion Capital Partners, Professor of Translational Gastroenterology Leiden University Medical Center and is the interim CEO of Amsterdam Molecular Therapeutics. He received his medical degree and doctorate of philosophy from the University of Amsterdam on the biological activities of bacterial lipopolysaccharides in humans. He worked in the Laboratory for Medical Biochemistry, Rockefeller University, New York. In 1995 he became director of the laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam, and continued to work on therapeutic signal transduction inhibition, gene therapy, and (genetically engineered) probiotics. From 2001 until 2004, he chaired the Department of Gastroenterology and Hepatology at the Academic Medical Center in Amsterdam. Sander van Deventer has been a member of advisory panels of the Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products. He has authored more than 80 book chapters, 350 peer review scientific papers. 

Hartmut Wekerle is Professor and Director at the Max Planck Institute of Neurobiology in Munich. He has served as Chairman (Dean) of the Biological-Medical Section of the Max Planck Society (1999-2002). Since his postdoctoral training at the Weizmann Institute, Wekerle's interest is focused on the cellular basis of immunological self-tolerance and autoimmunity. Specifically he has been studying the pathogenesis of autoimmune nervous diseases, especially Multiple Sclerosis, over the past 20 years. He serves on advisory boards of several national and international research institutions, including MS societies, and is member of the editorial boards of numerous international journals. His scientific prizes and awards include: Jung Prize for Science and Research (1982), Duchenne Prize (1984), Zülch-Prize (1999) Charcot Award (International Federation of MS Societies, 2001), Louis D Prize (Grand Prix des Academies des Sciences, Paris, 2002), Betty and David Koetser Award 2005. He is Honorary Professor, University of Munich (1993), member of LEOPOLDINA (German Academy of Natural Scientists, 2002), and president of the International Society of Neuroimmunology.

Professor and Head of the Institute of Experimental Immunology, Department of Pathology at the University of Zurich. Among other professional memberships, he is a member of the Swiss Society of Allergy and Immunology, the Swiss Society of Pathology, the Swiss Society of Microbiology, the Swiss society of Cell and Molecular Biology and the US Academy of Sciences. He is a member of the board of directors of Novartis International AG and Cytos AG, and an advisor to different institutes and biotechnology companies. Dr. Zinkernagel is specialized in infectious diseases and immunopathology. He is a pioneer in research on self-nonself discrimination in immunology. He received the Nobel Prize in medicine (1996).